Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
C3 glomerulopathy (C3G) is a rare complement-mediated kidney disease. In the absence of head-to-head randomized-controlled trials (RCTs), anchored indirect treatment comparisons (ITCs) were conducted to assess the relative efficacy of two complement pathway inhibitors, pegcetacoplan (targeted C3/C3b inhibitor) and iptacopan (factor B inhibitor), in patients with C3G.
Data were extracted from phase 3 RCTs for pegcetacoplan (VALIANT [NCT05067127]) and iptacopan (APPEAR-C3G [NCT04817618]). A common placebo arm in both trials allowed 2 anchored ITCs to be performed: Bucher method (primary analysis – preserves randomization) and matching-adjusted indirect comparison (MAIC; supportive analysis – adjusts for trial differences). Relative efficacy was assessed for key outcomes at 6 months, including urine protein-creatinine ratio (UPCR), estimated glomerular filtration rate (eGFR) and composite renal endpoint (≥50% reduction from baseline in UPCR and ≤15% reduction in eGFR). Results were reported as mean or risk difference with 95% confidence intervals.
The Bucher method demonstrated that pegcetacoplan was associated with a significantly greater reduction in UPCR from baseline compared with iptacopan, along with a significantly greater proportion of patients achieving both UPCR reduction to <1 g/g and by ≥50% and the composite renal endpoint (Figure). The change from baseline in eGFR favored pegcetacoplan versus iptacopan numerically but did not reach statistical significance. Results from the MAIC were generally consistent across these endpoints. Updated analyses, which show consistent results at 12 months, will also be presented at the meeting.
These 2 ITCs indicate that pegcetacoplan was superior to iptacopan in lowering proteinuria levels and achieving the composite renal endpoint in patients with C3G. The findings from this analysis may help guide clinicians managing patients with this rare condition. This abstract was also submitted for the ASN Kidney Week 2025 congress.
